High FASN expression was demonstrated in as many as 94.1% of patients with FIGO stage IV ovarian cancer but in only 1.25% of patients with stage I ovarian cancer (Ueda et al., 2010b; Cai et al., 2015). This evidence concerns the gene FASN and ovarian carcinoma.